D. Berz, D. Pinato, M. Barve, J. Pulini, J. Bowman, M.L. Johnson
{"title":"159TiP 两项 I 期研究,评估小分子口服 PD-L1 抑制剂 INCB099280 与 adagrasib(INCB 99280-204 [研究 204])或 ipilimumab(INCB 99280-205 [研究 205])联合治疗晚期实体瘤成人患者的安全性和有效性","authors":"D. Berz, D. Pinato, M. Barve, J. Pulini, J. Bowman, M.L. Johnson","doi":"10.1016/j.iotech.2023.100670","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":192507,"journal":{"name":"Immuno-Oncology and Technology","volume":" 46","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"159TiP Two phase I studies assessing the safety and efficacy of the small molecule oral PD-L1 inhibitor INCB099280 in combination with adagrasib (INCB 99280-204 [study 204]) or ipilimumab (INCB 99280-205 [study 205]) in adults with advanced solid tumors\",\"authors\":\"D. Berz, D. Pinato, M. Barve, J. Pulini, J. Bowman, M.L. Johnson\",\"doi\":\"10.1016/j.iotech.2023.100670\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":192507,\"journal\":{\"name\":\"Immuno-Oncology and Technology\",\"volume\":\" 46\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-Oncology and Technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.iotech.2023.100670\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-Oncology and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.iotech.2023.100670","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
159TiP Two phase I studies assessing the safety and efficacy of the small molecule oral PD-L1 inhibitor INCB099280 in combination with adagrasib (INCB 99280-204 [study 204]) or ipilimumab (INCB 99280-205 [study 205]) in adults with advanced solid tumors